COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT

被引：0
|
作者：
Vorobyev, P. [1 ]
Krasnova, L. [2 ]
Borisenko, O. [1 ]
Lukyantseva, D. [2 ]
Bashlakova, L. [2 ]
机构：
[1] Russian Soc Pharmacoecon & Outcomes Res, Moscow, Russia
[2] Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A41 / A41
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of enoxaparin versus aspirin in the prevention of venous thromboembolism after total hip or knee arthroplasty: an analysis from the CRISTAL cluster-randomized trial
    Huxley, Nicola
    Sidhu, Verinder
    Kelly, Thu- Lan
    Pratt, Nicole L.
    Graves, Stephen E.
    Buchbinder, Rachelle
    Adie, Sam
    Cashman, Kara
    Ackerman, Ilana
    de Steiger, Richard
    Lorimer, Michelle
    Naylor, Justine M.
    Harris, Ian A.
    Harris., Anthony
    BONE & JOINT JOURNAL, 2024, 106B (06): : 589 - 595
  • [32] Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement surgery (TKR)
    Bradley-Kennedy, C.
    Wolowacz, S. E.
    Roskell, N. S.
    Plumb, J. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 786 - 786
  • [33] Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty
    Levitan, Bennett
    Yuan, Zhong
    Turpie, Alexander G. G.
    Friedman, Richard J.
    Homering, Martin
    Berlin, Jesse A.
    Berkowitz, Scott D.
    Weinstein, Rachel B.
    DiBattiste, Peter M.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 157 - 167
  • [34] Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials
    Friedman, R. J.
    Dahl, O. E.
    Rosencher, N.
    Caprini, J. A.
    Kurth, A. A.
    Francis, C. W.
    Clemens, A.
    Hantel, S.
    Schnee, J. M.
    Eriksson, B. I.
    THROMBOSIS RESEARCH, 2010, 126 (03) : 175 - 182
  • [35] Rivaroxaban Versus Enoxaparin For Prevention Of Venous Thromboembolism In Elective Total Hip Replacement: A Retrospective Cohort Study
    Young, Stephanie W.
    Kielly, Jason
    Mathews, Maria
    Furey, Andrew
    Grewal, Kuljit
    Bishop, Lisa D.
    Dillon, Carla
    Lee, Tiffany
    Hawboldt, John
    Twells, Laurie
    BLOOD, 2013, 122 (21)
  • [36] Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands
    Stevanovic, J.
    de Jong, L. A.
    Kappelhoff, B. S.
    Dvortsin, E. P.
    Voorhaar, M.
    Postma, M. J.
    PLOS ONE, 2016, 11 (10):
  • [37] Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands
    Heisen, Marieke
    Treur, Maarten J.
    Heemstra, Harald E.
    Giesen, Eric B. W.
    Postma, Maarten J.
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (08) : 813 - 824
  • [38] Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China
    Xiaoyu Yan
    Xiaohua Gu
    Zhenxing Xu
    Houweng Lin
    Bin Wu
    Advances in Therapy, 2017, 34 : 466 - 480
  • [39] COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT IN CHINA
    Yan, X. Y.
    Gu, X. H.
    Zhou, L.
    Lin, H. W.
    Wu, B.
    VALUE IN HEALTH, 2016, 19 (07) : A866 - A866
  • [40] Cost-effectiveness of venous thromboembolism prophylaxis after total hip replacement
    Caprini, JA
    Arcelus, JL
    Kudrna, JC
    Sehgal, LR
    Oyslender, M
    Maksimovic, D
    MacDougall, A
    PHLEBOLOGY, 2002, 17 (3-4) : 126 - 133
12345